Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Accumulated Expenses (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Accumulated Expenses for 11 consecutive years, with $16.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses changed N/A to $16.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $16.3 million for FY2025, N/A changed from the prior year.
  • Accumulated Expenses for Q4 2025 was $16.3 million at Crescent Biopharma, up from $9.0 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $16.3 million in Q4 2025, with the low at $3528.0 in Q1 2025.
  • Average Accumulated Expenses over 5 years is $4.1 million, with a median of $2.0 million recorded in 2021.
  • Peak annual rise in Accumulated Expenses hit 1941.54% in 2025, while the deepest fall reached 99.47% in 2025.
  • Over 5 years, Accumulated Expenses stood at $348752.0 in 2021, then decreased by 13.79% to $300653.0 in 2022, then surged by 32.96% to $399763.0 in 2023, then grew by 9.85% to $439130.0 in 2024, then surged by 3621.9% to $16.3 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $16.3 million, $9.0 million, and $7.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.